BioAsset

Insights / All articles

Research

BioAsset Autopsies: The Intarcia Story

By Dmitry Vysotskiy, Founder & President at BioAsset · 5 slides

Intarcia Therapeutics raised $1.9 billion to put up to a year of diabetes medication into an implant the size of a matchstick. The FDA turned the product down twice, and the whole firm went under. This autopsy, part of a new series, treats it as a $1.9B+ lesson in relying on a single product.

The company and its technology

The company was founded as BioMedicines in 1995 and renamed Intarcia Therapeutics in 2004. Its technology was ITCA 650, a matchstick-sized osmotic pump implanted under the skin that continuously delivered exenatide, a GLP-1 agonist, for Type 2 diabetes for 6-12 months.

An osmotic pump is a miniature, implantable device or oral tablet that delivers drugs or agents continuously at a controlled rate using osmotic pressure. In the implant, a semipermeable membrane sits at one end, followed by an osmotic engine, a piston and a drug reservoir, with the drug formulation released at the other end.

Instead of daily or weekly injections (like Ozempic), one tiny implant gives steady medication for a year. This technology was very enticing for patients.

All of the $1.9 billion in funding depended on FDA approval. After Intarcia filed for bankruptcy and proceeded to liquidation, its assets were acquired by i2o Therapeutics, which continued to revamp the implant pump technology and tried to prove that it works. The FDA rejected it in 2024, and the program is now fully dead.

Timeline

What went wrong

The manufacturing process was complex. The osmotic pump required highly precise manufacturing with no room for error, because tiny variations lead to inconsistent drug delivery, and that is a patient safety risk. The FDA’s manufacturing standards for implantable devices are extremely strict.

The company depended on one product. Intarcia put all its funds and energy into one basket, with no backup pipeline, and when ITCA 650 failed the entire company fell with it. It had other programs and “products,” but they all required ITCA 650 approval to advance further.

The regulatory burden was doubled. ITCA 650 had to satisfy both drug and device FDA standards, since combination products face stricter scrutiny, in this case double.

The timing was bad. By 2017-2020, weekly GLP-1s like Ozempic were being commercialized and gaining popularity. The industry began to move faster than Intarcia could pivot, which further shrank the convenience advantage of ITCA 650.

Survival tips

Partner earlier for manufacturing. Intarcia should have attempted to partner with big pharma companies that had manufacturing expertise. Pride and equity concerns brought the company downhill.

Diversify. It should have developed multiple products that were not fully dependent on the osmotic pump platform, as a potential safeguard.

Use a licensing strategy. Intarcia could potentially have licensed the pump technology to other firms, generating some revenue while revamping and fixing ITCA 650.

Pivot after the first rejection. The FDA’s first rejection in 2017 should have served as a warning sign and a push toward another direction. Intarcia could have attempted to sell assets and focus on a different delivery system, yet stubbornness resulted in its end.

In another universe, Intarcia shakes hands with a partner such as Lilly, J&J, Pfizer or Novo Nordisk.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.